Rees S A, Curtis M J
Department of Pharmacology, King's College, University of London, United Kingdom.
Cardiovasc Res. 1993 Mar;27(3):453-8. doi: 10.1093/cvr/27.3.453.
Tacrine was used as a tool to examine whether block of inward rectifying potassium current (IK1) represents a mechanism for suppression of arrhythmias induced by ischaemia and reperfusion.
Isolated rat hearts (n = 10-12 per group) were subjected to 30 min left regional ischaemia followed by reperfusion with and without tacrine. Rat heart was used to permit delayed rectifier (IK) block to be disregarded in interpretation of results (rat ventricle is deficient in functional IK).
The incidence of ischaemia-induced ventricular fibrillation was reduced from 70% to 42%, 17% (p < 0.05), and 0% (p < 0.05) in hearts perfused with 0, 0.1, 1.0, and 10.0 microM tacrine. Likewise, the incidence of reperfusion induced ventricular fibrillation was reduced from 100% to 90%, 75%, and 50% (p < 0.05), respectively. Indirect evidence of repolarisation delay by tacrine was provided by QT widening; for example, 15 min after the onset of ischaemia, QT (at 100% repolarisation) was increased from 194(SEM 6) to 231(17), 235(13) (p < 0.05), and 341(24) ms (p < 0.05) by increasing concentrations of drug. QT interval measured in individual hearts during ischaemia correlated inversely with arrhythmia score (r2 = 0.392; p < 0.001). Tacrine had no effect on RR interval, coronary flow, recovery of flow during reperfusion, or occluded zone size. Tacrine caused bradycardia (significant at the 1.0 and 10.0 microM concentrations). In additional hearts (n = 12 per group), reversal of 10.0 microM tacrine-induced sinus bradycardia by left atrial pacing (5 Hz) significantly reduced tacrine induced QT widening (p < 0.05), and increased the incidence of ventricular fibrillation from 0% to 42% (although significant antiarrhythmic and QT widening effects were still present); 10.0 microM tacrine failed to reduce the incidence of reperfusion induced ventricular fibrillation in paced hearts (92% incidence v 100% in controls).
The novel antiarrhythmic effects of tacrine, a drug with established blocking action on IK, IK1, and slow inward current, appear to result from QT widening in the rat (dependent partly on IK1 blockade in the ventricles and partly on drug induced sinus bradycardia).
使用他克林作为工具,研究内向整流钾电流(IK1)的阻断是否代表抑制缺血再灌注诱发心律失常的一种机制。
将离体大鼠心脏(每组10 - 12个)进行30分钟左区域缺血,然后在有或没有他克林的情况下进行再灌注。使用大鼠心脏以便在结果解释中忽略延迟整流钾电流(IK)阻断(大鼠心室中功能性IK缺乏)。
在灌注0、0.1、1.0和10.0微摩尔/升他克林的心脏中,缺血诱发的心室颤动发生率分别从70%降至42%、17%(p < 0.05)和0%(p < 0.05)。同样,再灌注诱发的心室颤动发生率分别从100%降至90%、75%和50%(p < 0.05)。QT间期延长提供了他克林引起复极延迟的间接证据;例如,缺血开始后15分钟,随着药物浓度增加,QT(在100%复极时)从194(标准误6)增加到231(17)、235(13)(p < 0.05)和341(24)毫秒(p < 0.05)。缺血期间在各个心脏中测量的QT间期与心律失常评分呈负相关(r2 = 0.392;p < 0.001)。他克林对RR间期、冠状动脉血流量、再灌注期间的血流恢复或梗死区大小没有影响。他克林引起心动过缓(在1.0和10.0微摩尔/升浓度时显著)。在另外的心脏(每组12个)中,通过左心房起搏(5赫兹)逆转10.0微摩尔/升他克林诱发的窦性心动过缓显著减少了他克林引起的QT间期延长(p < 0.05),并使心室颤动发生率从0%增加到42%(尽管仍存在显著的抗心律失常和QT间期延长作用);10.0微摩尔/升他克林未能降低起搏心脏中再灌注诱发的心室颤动发生率(发生率为92%,而对照组为100%)。
他克林是一种对IK、IK1和慢内向电流具有既定阻断作用的药物,其新的抗心律失常作用似乎源于大鼠中的QT间期延长(部分取决于心室中IK1阻断,部分取决于药物诱发的窦性心动过缓)。